Table 1 Baseline characteristics
Clinical characteristics | General population (n = 4,324,545) | Cancer population (n = 316,040) |
|---|---|---|
Male sex | 2,176,883 (50.3) | 153,258 (48.5) |
Median (SD*) age (years) | 44.8 (18.0) | 67.0 (13.3) |
Comorbidity: | ||
Stroke | 63,619 (1.5) | 19,589 (6.2) |
Ischemic heart disease | 64,596 (1.5) | 17,297 (5.5) |
Heart failure | 22,271 (0.5) | 6226 (2.0) |
Hypertension | 179,184 (4.1) | 111,157 (35.2) |
Vascular disease | 83,119 (1.9) | 25,590 (8.1) |
Previous bleeding | 27,104 (0.6) | 36,996 (11.7) |
Chronic obstructive pulmonary disease | 19,639 (0.5) | 19,127 (6.1) |
Chronic kidney disease | 36,595 (0.9) | 8962 (2.8) |
Misuse of alcohol or psychoactive substance | 73,056 (1.7) | 17,533 (5.6) |
Hyperthyroid disease | 29,945 (0.7) | 9704 (3.1) |
Previous embolus | 81,350 (1.9) | 26,708 (8.5) |
Liver disease | 27,104 (0.6) | 9395 (3.0) |
Pharmacotherapy | ||
Calcium channel blocker | 154,619 (3.6) | 43,591 (13.8) |
ACE† inhibitors | 173,182 (4.0) | 67,737 (21.4) |
Beta blockers | 158,308 (3.7) | 42,629 (13.5) |
Spironolactone | 18,023 (0.4) | 9132 (2.9) |
Loop diuretic | 118,914 (2.8) | 35,159 (11.1) |
Thiazide diuretic | 168,222 (3.9) | 43,289 (13.7) |
Aspirin | 175,178 (4.1) | 60,598 (19.2) |
Clopidogrel | 1444 (0.03) | 4488 (1.4) |
Warfarin | 1558 (0.5) | 7376 (2.3) |
Digoxin | 41,430 (1.0) | 6852 (2.2) |
Cholesterol-lowering drug | 62,599 (1. 5) | 50,301 (15.9) |
Glucose-lowering medication | 8791 (2.9) | 22,979 (7.2) |
Inhalation medication | 222,169 (5.1) | 40,355 (12.8) |